Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PFIZER AGREEMENT WITH NORTHWESTERN IN ANTI-TRUST SUIT STIPULATES

Executive Summary

PFIZER AGREEMENT WITH NORTHWESTERN IN ANTI-TRUST SUIT STIPULATES that the whslr. will not sell Pfizer products to its Pay 'N Save outlets. "Pfizer agreed to sell to Northwestern products at whsle. price where products are not re-sold to Pay 'N Save affiliated outlets," a Pfizer representative told "The Pink Sheet." The mfr. and Northwestern settled the suit on Oct. 12. Pfizer is the fourth company to reach a long-term settlement with Northwestern. Previously, Lilly, American Home Products, and Sandoz reached agreements with the whslr. ("The Pink Sheet" Oct. 1, p. 14). Lilly's agreement calls for the firm to supply Northwestern through June 1985. SmithKline remains as the sole mfr. defendant in the lawsuit. Last May, SmithKline arrived at an interim agreement with Northwestern's customer, the Velocity Hospital Buying Group, to provide normal chargeback allowances, pending the outcome of the suit. The case is scheduled to go to trial on Feb. 25, 1985.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel